Factors affecting survival and prognosis in extensive stage small cell lung cancer

医学 阶段(地层学) 肺癌 肿瘤科 癌症 内科学 生物 古生物学
作者
Mert Erciyestepe,Ömer Burak Ekinci,Hale Gülçin Yıldırım Doğan,Ahmet Emin Öztürk,Okan Aydın,Aslı Büyükkuşcu,Tugay Atasever,Beyza Soylu Uslu,Kübra Akkaya,Emir Çelik,Kayhan Ertürk,Muhammed Mustafa Atçı
出处
期刊:BMC Pulmonary Medicine [BioMed Central]
卷期号:25 (1): 160-160 被引量:8
标识
DOI:10.1186/s12890-025-03625-w
摘要

Although chemotherapy significantly improves the quality of life and prolongs survival in patients with extensive-stage small cell lung cancer (ES-SCLC), relapse is almost inevitable, with only 5% of patients surviving two years after the initial diagnosis. Prophylactic cranial irradiation (PCI) is considered for patients who achieve a complete response, as it has been shown to improve survival rates in this population. Recent studies have also demonstrated that adding PD-L1 inhibitors, such as atezolizumab or durvalumab, to chemotherapy in first-line treatment significantly enhances survival compared to chemotherapy alone. Our study was conducted retrospectively at a single center, including 280 patients with ES-SCLC who began therapy at our institution between July 2009 and February 2023. Patients who underwent thoracic residual radiotherapy (p< 0.001) and PCI (p< 0.001) showed statistically significant improvements in OS. In the first-line treatment group, the median overall survival (OS) for patients receiving cisplatin+etoposide was 12.0 months (10.71 - 13.28), while those treated with carboplatin+etoposide had a median OS of 7.0 months (4.58 - 9.41). For patients receiving carboplatin+etoposide+atezolizumab, the median OS was 35.0 months (21.32 - 48.67), and a statistically significant difference was observed (p< 0.001). In our study, the median OS was 7 months in patients who received ≤ 4 cycles of treatment in the first line and 14 months in patients who received > 4 cycles of treatment. After first-line treatment, the proportion of patients with progression-free survival (PFS) between 0 - 3 months was 21%, and between 3 - 6 months was 24%. PFS was notably worse in those with bone, liver, or brain metastases at diagnosis in the first-line treatment. Multivariate analysis revealed that carboplatin+etoposide+atezolizumab in the first line and cisplatin+etoposide in the second line reduced the risk of both progression and death, while PCI reduced the risk of death. In conclusion, ES-SCLC remains one of the most challenging malignancies, characterized by poor survival rates and short progression-free intervals. Multiple factors influence OS and PFS, some of which are intrinsic to the patient and disease at diagnosis. In contrast, others, such as treatment modalities, the number of treatment cycles, and the application of radiotherapy, can be modified by clinicians.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
1秒前
Jarvis完成签到,获得积分10
1秒前
3秒前
ayeben发布了新的文献求助10
3秒前
花深粥完成签到 ,获得积分10
4秒前
Shulei发布了新的文献求助10
4秒前
少爷完成签到,获得积分10
5秒前
实验狗发布了新的文献求助10
5秒前
李健的小迷弟的应助被chole采纳,获得10
5秒前
悦耳筮的应助被DW采纳,获得50
5秒前
5秒前
乐乐的应助被白rain采纳,获得10
5秒前
Nole的应助被薛定谔的猫爱摸鱼采纳,获得10
7秒前
863完成签到,获得积分10
7秒前
8秒前
8秒前
9秒前
星辰大海的应助被yydragen采纳,获得30
10秒前
cdercder的应助被缓慢的清涟采纳,获得10
11秒前
科研通AI65的应助被emmm采纳,获得10
12秒前
孜孜发布了新的文献求助10
13秒前
墨染完成签到 ,获得积分10
14秒前
DD发布了新的文献求助10
15秒前
16秒前
17秒前
打打的应助被DW采纳,获得10
18秒前
515完成签到,获得积分10
20秒前
20秒前
杨安安完成签到,获得积分10
21秒前
夏爽2023完成签到,获得积分10
23秒前
交给不着急完成签到,获得积分10
24秒前
25秒前
朱雀发布了新的文献求助10
25秒前
26秒前
yang发布了新的文献求助10
26秒前
27秒前
28秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188339
求助须知:如何正确求助?哪些是违规求助? 9576114
关于积分的说明 21845532
捐赠科研通 7786371
什么是DOI,文献DOI怎么找? 3435279
关于科研通互助平台的介绍 2559581
邀请新用户注册赠送积分活动 2482182